Search Result

Results for "

cMyc

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Myc (35) Akt (1) Antibiotic (1) Apoptosis (15) Autophagy (8) Bacterial (2) Bcl-2 Family (1) Casein Kinase (1) Caspase (3) CDK (4) Deubiquitinase (3) DNA/RNA Synthesis (1) Endogenous Metabolite (1) Epigenetic Reader Domain (14) Fatty Acid Synthase (FASN) (1) Fungal (1) FXR (1) GSK-3 (2) Histone Acetyltransferase (1) Histone Methyltransferase (2) JNK (1) KLF (1) Molecular Glues (1) p38 MAPK (3) PPAR (1) PROTACs (4) Sirtuin (2) STAT (1) Topoisomerase (1) Wnt (1) β-catenin (3)
By Research Areas:	Cancer (65) Cardiovascular Disease (2) Infection (6) Inflammation/Immunology (5) Metabolic Disease (1)

By Targets:

c-Myc (35)

Akt (1)

Antibiotic (1)

Apoptosis (15)

Autophagy (8)

Bacterial (2)

Bcl-2 Family (1)

Casein Kinase (1)

Caspase (3)

CDK (4)

Deubiquitinase (3)

DNA/RNA Synthesis (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (14)

Fatty Acid Synthase (FASN) (1)

Fungal (1)

FXR (1)

GSK-3 (2)

Histone Acetyltransferase (1)

Histone Methyltransferase (2)

JNK (1)

KLF (1)

Molecular Glues (1)

p38 MAPK (3)

PPAR (1)

PROTACs (4)

Sirtuin (2)

STAT (1)

Topoisomerase (1)

Wnt (1)

β-catenin (3)

By Research Areas:

Cancer (65)

Cardiovascular Disease (2)

Infection (6)

Inflammation/Immunology (5)

Metabolic Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

MCE Kits

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: c-Myc

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148836

c-Myc inhibitor 6	c-Myc	Infection Cardiovascular Disease Cancer
c-Myc inhibitor 6 (compound A102) is a *c-Myc* inhibitor. c-Myc inhibitor 6 decreases cancer cell viability and degrades c-Myc protein. c-Myc inhibitor 6 can be used for the research of c-Myc imbalance, such as cancer, cardiovascular diseases, and viral infection .

HY-162294

c-Myc inhibitor 13	c-Myc	Cancer
c-Myc inhibitor 13 (compound A6) is a c-MYC transcription inhibitor. c-Myc inhibitor 13 selectively stabilizes c-MYC G4 and inhibits G4-associated c-MYC transcription .

HY-148838

c-Myc inhibitor 8	c-Myc	Cancer
c-Myc inhibitor 8 (compound 56) is a *c-Myc* inhibitor. c-Myc inhibitor 8 effectively inhibits cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 can be used for cancer research .

HY-148837

c-Myc inhibitor 7	c-Myc Casein Kinase	Infection Cardiovascular Disease Cancer
c-Myc inhibitor 7 is a *c-Myc* inhibitor and a multiple target protein degrader. c-Myc inhibitor 7 effective degrades *c-MYC, CK1α, GSPT1* and IKZF1/2/3 proteins in a variety of tumor cells. c-Myc inhibitor 7 can be used for c-Myc high expression related disease research, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection .

HY-148839

c-Myc inhibitor 9	c-Myc	Cancer
c-Myc inhibitor 9 (compound 332) is a *c-Myc* inhibitor with an logEC₅₀ of ≥6. c-Myc inhibitor 9 inhibits tumor growth in nude mouse models. c-Myc inhibitor 9 can be used for cancer research .

HY-160549

c-Myc inhibitor 14	c-Myc	Cancer
c-Myc inhibitor 14 (Compound 13A) is a *c-Myc* protein inhibitor. The IC₅₀ value of HL60 inhibitor is <100 nM. c-Myc inhibitor 14 shows antitumor activity .

HY-145843

c-Myc inhibitor 5	c-Myc	Cancer
c-Myc inhibitor 5 (DA3) is a fluorescent, long chain-bridged bispurine that selectively targets the c-MYC G-quadruplex (K_D of 16 μM). c-Myc inhibitor 5 shows inhibition on c-MYC expression rather than other G4-driven oncogenes .

HY-155507

c-Myc inhibitor 11	c-Myc	Cancer
c-Myc inhibitor 11 (Compound 67e) is a *c-MYC* inhibitor (pEC₅₀: 6.4). c-Myc inhibitor 11 has high clearance levels, moderate volume of distribution and short half-life in rat pharmacokinetic assay. c-Myc inhibitor 11 can be used for cancer research .

HY-155508

c-Myc inhibitor 12

c-Myc Cancer

c-Myc inhibitor 12 (compound 67h) is an inhibitor of c-Myc with a pEC₅₀ of 6.4 .

c-Myc inhibitor 12	c-Myc	Cancer
c-Myc inhibitor 12 (compound 67h) is an inhibitor of c-Myc with a pEC₅₀ of 6.4 .

HY-154839

c-Myc inhibitor 10	c-Myc	Cancer
c-Myc inhibitor 10 (compound 17), a c-Myc inhibitor, exhibits increased cellular potency, consistent with an increase in permeability with methylation of the morpholine nitrogen .

HY-139885

c-Myc inhibitor 4

c-Myc Cancer

c-Myc inhibitor 4 is a potent, orally bioavailable c-MYC-reducing compound.

c-Myc inhibitor 4	c-Myc	Cancer
c-Myc inhibitor 4 is a potent, orally bioavailable c-MYC-reducing compound.

HY-12702

10058-F4 Maximum Cited Publications 34 Publications Verification	c-Myc Autophagy	Cancer
10058-F4 is a *c-Myc* inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

HY-147973

IZTZ-1	c-Myc Apoptosis	Cancer
IZTZ-1, an imidazole-benzothiazole conjugate, is a c-MYC G4 ligand. IZTZ-1 is able to downregulate the *c-MYC* expression by stabilizing c-MYC G4. IZTZ-1 induces cell cycle arrest, apoptosis, thereby inhibiting cell proliferation in B16 cells. IZTZ-1 shows antitumor activity, and can be used for melanoma research .

HY-124129

10074-A4

c-Myc Cancer

10074-A4 is a c-Myc inhibitor. 10074-A4 could bind to c-Myc_370-409 at different sites along the peptide chain. 10074-A4 has anticancer effects .
HY-111411

IZCZ-3

2 Publications Verification

c-Myc Autophagy Cancer

IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity .

10074-A4	c-Myc	Cancer
10074-A4 is a c-Myc inhibitor. 10074-A4 could bind to c-Myc_370-409 at different sites along the peptide chain. 10074-A4 has anticancer effects .

IZCZ-3 2 Publications Verification	c-Myc Autophagy	Cancer
IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity .

HY-145898

WBC100 14-D-Valine-TPL	c-Myc Molecular Glues	Cancer
WBC100 (14-D-Valine-TPL) is a potent, selective, and orally active *c-Myc* molecule glue degrader. WBC100 is a c-Myc degrader and targets ubiquitin E3 ligase CHIP mediated 26S proteasome pathway. WBC100 is used for c-Myc overexpressing tumors research .

HY-149513

EP12	c-Myc Apoptosis	Cancer
EP12 is a *c-Myc* inhibitor. EP12 is a c-Myc G4 stabilizer. EP12 induces apoptosis and DNA damage in multiple myeloma cells. EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway. EP12 inhibits multiple myeloma growth .

HY-104072

BRD4-IN-3	Epigenetic Reader Domain	Infection Inflammation/Immunology
BRD4-IN-3 (compound 141) is a potent BRD4 inhibitor with an IC₅₀ of <0.5 µM. BRD4-IN-3 shows cytoxicity for MYC-Raji with an IC₅₀ value of >1 µM .

HY-135691

hnRNPK-IN-1	c-Myc Apoptosis	Cancer
hnRNPK-IN-1 is a heterogeneous nuclear ribonucleoprotein K (hnRNPK) binding ligand with K_d values of 4.6 μM and 2.6 μM measured with SPR and MST, respectively. hnRNPK-IN-1 inhibits c-myc transcription by disrupting the binding of hnRNPK and c-myc promoter. hnRNPK-IN-1 induces Hela cells apoptosis and has strongly anti-tumor activities .

HY-124811

IRES-C11	c-Myc	Cancer
IRES-C11 is a spectfic c-MYC internal ribosome entry site (IRES) translation inhibitor. IRES-C11 blocks the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. IRES-C11 does not inhibits BAG-1, XIAP and p53 IRESes .

HY-156673

m-Se3

c-Myc Cancer

m-Se3 is a potent and selective c-MYC transcription inhibitor that can inhibit tumor growth and has anti-cancer activity .
HY-122698

CCI-007

Apoptosis Cancer

CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC₅₀ values of 2.5-6.2 μM in sensitive cells .

m-Se3	c-Myc	Cancer
m-Se3 is a potent and selective *c-MYC* transcription inhibitor that can inhibit tumor growth and has anti-cancer activity .

CCI-007	Apoptosis	Cancer
CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC₅₀ values of 2.5-6.2 μM in sensitive cells .

HY-148333

MS177	PROTACs Histone Methyltransferase Apoptosis	Cancer
MS177 is an effective and fast-acting EZH2 degrader. MS177 is a PROTAC that consists of a CRBN ligand, linker, and a potent enzymatic EZH2 inhibitor C24 (C24 IC₅₀): 12 nM). MS177 effectively depletes both canonical EZH2–PRC2 and noncanonical EZH2–cMyc complexes. MS177 induces leukaemia cell growth inhibition, apoptosis and cell cycle progression arrest .

HY-121418

Lusianthridin	c-Myc	Cancer
Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling .

HY-12703

KSI-3716 1 Publications Verification	c-Myc Autophagy	Cancer
KSI-3716 is a potent *c-Myc* inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer .

HY-151471

Anticancer agent 84	c-Myc	Cancer
Anticancer agent 84 is an anticancer agent. Anticancer agent 84 represses the transcription of c-MYC by stabilizing the G-quadruplex (G4) structure. Anticancer agent 84 can be used for the research of cancer .

HY-155815

MS9715	Histone Methyltransferase PROTACs	Cancer
MS9715 is a potent and seletive NSD3-targeting PROTAC. MS9715 is designed by BI-9321, which binds NSD3’s PWWP1 domain, with an E3 ligase VHL ligand.?MS9715 has the potental for?NSD3-dependent cancer treatment research .

HY-147651

β-catenin-IN-4	β-catenin	Cancer
β-catenin-IN-4 (Compound 39) is a β-catenin inhibitor with a K_i of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc .

HY-100669

Mycro 3 5 Publications Verification	c-Myc Autophagy	Cancer
Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .

HY-112316

BAY1238097	Epigenetic Reader Domain	Cancer
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC₅₀ <100 nM).

HY-134761

EN4	c-Myc	Cancer
EN4 is a covalent ligand that targets cysteine 171 (C171) of MYC. EN4 is selective for *c-MYC* over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis .

HY-112799

DK419	Wnt β-catenin	Cancer
DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC₅₀ of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK .

HY-124447

BTYNB	c-Myc	Cancer
BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA (IC₅₀=5 μM). BTYNB exhibits selectivity and effectiveness against IMP1-postive cancer cell lines. BTYNB can be used for cancer research .

HY-100653

AZD5153	Others	Cancer
AZD5153 (Compound 13) is a trivalent triazolpyrazine bromide domain (BRD), bromodomain and extraterminal (BET) inhibitor. AZD5153 has down-regulated c-Myc gene and tumor growth inhibition activity. AZD5153 can be used in the study of BET small molecule inhibitors .

HY-163108

ATAD2-IN-1	Epigenetic Reader Domain Apoptosis c-Myc	Cancer
ATAD2-IN-1 (compound 19f) is a potent ATAD2 inhibitor (IC₅₀: 0.27 μM) and can induce apoptosis. ATAD2-IN-1 also inhibits c-Myc activation and BT-549 cell migration .

HY-19759

SRT 2183 2 Publications Verification
SRT 2183 is a selective Sirtuin-1 (SIRT1) activator with an EC_1.5 value of 0.36 μM . SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels .

HY-109050

Alobresib 1 Publications Verification GS-5829	Epigenetic Reader Domain	Cancer
Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research .

HY-145408

CDK7/9-IN-1	CDK	Cancer
CDK7/9-IN-1 is a cyclin-dependent kinases 7/9 (CDK7/9) inhibitor. CDK7/9-IN-1 selectively inhibits CDK7 over CDK9. CDK7/9-IN-1 inhibits CDK7 with IC₅₀s of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. CDK7/9-IN-1 inhibits CDK9 with an IC₅₀ of 2.14 μM after 3 hours pre-incubation. CDK7/9-IN-1 can be used for the research of cancer .

HY-133131

PROTAC BRD4 Degrader-1	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-1 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 41.8 nM against BRD4 BD1. PROTAC BRD4 Degrader-1 can effectively degrade BRD4 protein and suppress *c-Myc* expression .

HY-134333

ICCB280	Apoptosis	Cancer
ICCB280 is a potent inducer of C/EBPα. ICCB280 exhibits anti-leukemic properties including terminal differentiation, proliferation arrest, and apoptosis through activation of C/EBPα and affecting its downstream targets (such as C/EBPε, G-CSFR and c-Myc) .

HY-17381A

Idarubicin 4-Demethoxydaunorubicin	Topoisomerase Bacterial Fungal Autophagy c-Myc DNA/RNA Synthesis Antibiotic	Infection Cancer
Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of *c-myc* expression. Idarubicin inhibits the growth of bacteria and yeasts .

HY-155153

CDK9-IN-24	Apoptosis CDK	Others
CDK9-IN-24 (compound 21a) is a highly selective CDK9 inhibitor with significant inhibitory effect on tumor growth. CDK9-IN-24 effectively blocks cell proliferation and induces apoptosis by downregulating Mcl-1 and c-Myc, and can be used in acute myeloid leukemia research .

HY-112316A

(R)-BAY1238097	Epigenetic Reader Domain	Cancer
(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome .

HY-126477

NNK	Endogenous Metabolite	Cancer
NNK is a nicotine-nitrosated derivative. NNK simultaneously stimulates Bcl2 phosphorylation exclusively at Ser ⁷⁰ and *c-Myc* at Thr ⁵⁸ and Ser ⁶² through activation of both ERK1/2 and PKCα . NNK induces survival and proliferation of human lung cancer cells. NNK can be used for lung cancer mice model structure .

HY-146445

P300 bromodomain-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
P300 bromodomain-IN-1 (Compoun 1u) is a potent p300 (EP300) bromodomain inhibitor with an IC₅₀ of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and apoptosis in OPM-2 cells .

HY-N11576

Secalonic acid D	Apoptosis GSK-3 c-Myc β-catenin	Cancer
Secalonic acid D is a toxic compound against tumor cells. Secalonic acid D can be isolated from the metabolites of Aspergillus aculeatus. Secalonic acid D activates GSK3-β, and degrades β-catenin. Thus, Secalonic acid D down-regulates *c-Myc* expression, arrests cell cycle at G1 phase, induces cell apoptosis .

HY-13241

Ralimetinib dimesylate 10+ Cited Publications LY2228820 dimesylate	p38 MAPK Autophagy Apoptosis	Inflammation/Immunology Cancer
Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.

HY-16291

APTO-253 10+ Cited Publications LOR-253; LT-253	c-Myc KLF Apoptosis	Inflammation/Immunology Cancer
APTO-253 (LOR-253) is a small molecule that inhibits *c-Myc* expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the Krüppel-like factor 4 (KLF4) tumor suppressor . APTO-253 has antiarthritic activity .

HY-13241A

Ralimetinib LY2228820	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc .

HY-149495

CP-07	PROTACs CDK	Cancer
CP-07 is a potent and selective PROTACCDK9 degrader (DC₅₀: 43 nM). CP-07 inhibits 22RV1 cell proliferation (IC₅₀: 62 nM) and colony formation by down-regulating Mcl-1 and c-Myc. CP-07 inhibits 22RV1 xenograft tumor growth. CP-07 can be used for research of prostate cancer .

Cat. No.	Product Name

HY-L064

Glutamine Metabolism Compound Library

903 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 903 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

HY-L039

Reprogramming Compound Library

2048 compounds

Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells.

MCE Reprogramming Compound Library contains a unique collection of 2048 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.

Species:	Human (13) Bovine (1) Mouse (5) Cynomolgus (1) Pig (1)
Tag:	His (22) SUMO (1) Myc (20)
Source:	HEK293 (8) P. pastoris (1) Sf9 insect cells (1) E. coli (12)

Cat. No.	Compare	Product Name	Species	Source

HY-P70260

	Enolase 1/ENO1 Protein, Human (His) rHuAlpha-enolase, His; Alpha-enolase; 2-phospho-D-glycerate hydro-lyase; C-myc promoter-binding protein; Enolase 1; MBP-1; MPB-1; Non-neural enolase; NNE; Phosphopyruvate hydratase; Plasminogen-binding protein; ENO1	Human	E. coli
	Alpha-enolase/Enolase 1 Protein, Human (His) expresses in E. coli with a His tag at the N-terminus. Alpha-enolase, a multifunctional protein, is a key glycolytic enzyme in the cytoplasm of prokaryotic and eukaryotic cells.

HY-P70260A

	Enolase 1/ENO1 Protein, Human (C-His) rHuAlpha-enolase, His; Alpha-enolase; 2-phospho-D-glycerate hydro-lyase; C-myc promoter-binding protein; Enolase 1; MBP-1; MPB-1; Non-neural enolase; NNE; Phosphopyruvate hydratase; Plasminogen-binding protein; ENO1	Human	E. coli
	The ENO1 Protein operates as a glycolytic enzyme, catalyzing the conversion of 2-phosphoglycerate to phosphoenolpyruvate. In addition to its role in glycolysis, ENO1 is implicated in various processes such as growth control, hypoxia tolerance, and allergic responses. Notably, it displays versatility by potentially functioning in the intravascular and pericellular fibrinolytic system, acting as a receptor and activator of plasminogen on the cell surface of diverse cell types including leukocytes and neurons. ENO1's ability to stimulate immunoglobulin production further underscores its multifaceted functions. Moreover, it binds to the myc promoter and acts as a transcriptional repressor, suggesting a regulatory role in gene expression. Additionally, ENO1 may function as a tumor suppressor, implicating its involvement in cellular processes that extend beyond glycolysis and impact critical aspects of growth control and immune responses. Enolase 1/ENO1 Protein, Human (C-His) is the recombinant human-derived Enolase 1/ENO1 protein, expressed by E. coli , with C-6*His labeled tag. The total length of Enolase 1/ENO1 Protein, Human (C-His) is 434 a.a., with molecular weight of 49 kDa.

HY-P700411

	*GCGR Protein, Human (HEK293, N-His, C-Myc)* glucagon receptor; GGR; GL-R; FLJ97182; MGC138246	Human	HEK293
	The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GCGR protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of GCGR Protein, Human (HEK293, N-His, C-Myc) is 111 a.a., with molecular weight of ~35 kDa.

HY-P700409

	*EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc)* Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	EGFR Protein, a receptor tyrosine kinase, binds various ligands like EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, initiating signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation, and recruitment of adapter proteins like GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs. EGFR can also trigger NF-kappa-B signaling, phosphorylate proteins like RGS16, and interact with MUC1, influencing G protein-coupled receptor signaling. Moreover, it enhances cell migration through interactions with CCDC88A, promoting EGFR signaling and triggering cell migration. Additionally, EGFR impacts learning, memory, and pain signaling. EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is the recombinant human-derived EGFR protein, expressed by HEK293, with C-Myc, N-10*His labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is 621 a.a., with molecular weight of 73.6 kDa.

HY-P700308

	*Stratifin Protein, Human (N-His, C-Myc)* 14-3-3 Protein Sigma; Epithelial Cell Marker Protein 1; Stratifin; SFN; HME1	Human	E. coli
	Stratifin (14-3-3 sigma), encoded by SFN, functions as a multifaceted adapter protein, engaging in diverse cellular processes by binding to partners via phosphoserine or phosphothreonine motifs. It regulates epithelial cell growth and protein synthesis with keratin 17 (KRT17) and potentially influences MDM2 autoubiquitination, activating p53. As a homodimer, it interacts in various complexes with proteins like GAB2, SAMSN1, SRPK2, COPS6, COP1, DAPK2, PI4KB, SLITRK1, and LRRK2, highlighting its versatile role in cellular processes and signaling pathways. Stratifin Protein, Human (N-His, C-Myc) is the recombinant human-derived Stratifin protein, expressed by E. coli, with N-10*His, C-Myc labeled tag. The total length of Stratifin Protein, Human (N-His, C-Myc) is 248 a.a., with molecular weight of ~34 kDa.

HY-P700529

	*AIF1 Protein, Bovine (N-His, C-Myc)* allograft inflammatory factor 1; IBA1; IRT1; AIF-1; IRT-1; protein G1	Bovine	E. coli
	AIF1 protein influences macrophage activation, modulating immune response and cellular activities. Its involvement implies broader influence on immune regulation and inflammation. Studying AIF1's mechanisms in macrophage activation can provide insights into its role in immune homeostasis and signaling pathways governing macrophage functions. AIF1 Protein, Bovine (N-His, C-Myc) is the recombinant bovine-derived AIF1 protein, expressed by E. coli, with C-Myc, N-10*His labeled tag. The total length of AIF1 Protein, Bovine (N-His, C-Myc) is 146 a.a., with molecular weight of 27.6 kDa.

HY-P700513

	*MIF Protein, Human (N-His, C-Myc)* MIF; macrophage migration inhibitory factor; GIF; GLIF; MMIF; phenylpyruvate tautomerase; glycosylation-inhibiting factor; EC 5.3.2.1; Glycosylation-inhibiting factor; Phenylpyruvate tautomerase	Human	E. coli
	The MIF protein is a pro-inflammatory cytokine that is critical for the innate immune response against bacterial pathogens. Its presence at sites of inflammation suggests a role in modulating macrophage function to promote host defense. MIF counteracts the anti-inflammatory effects of glucocorticoids. Although MIF exhibits tautomerase activity in vitro, its physiological substrates remain unknown, and the relevance of this activity to its cytokine function is unclear. MIF Protein, Human (N-His, C-Myc) is the recombinant human-derived MIF protein, expressed by E. coli, with C-Myc, N-10*His labeled tag. The total length of MIF Protein, Human (N-His, C-Myc) is 114 a.a., with molecular weight of 17.1 kDa.

HY-P700564

	*Galanin Protein, Human (N-His, C-Myc)* GAL; galanin prepropeptide; galanin , GALN; galanin peptides; galanin message associated peptide; GLNN; GMAP; galanin-related peptide; galanin-message-associated peptide; GALN; MGC40167	Human	E. coli
	Galanin exists as an endocrine hormone in the central and peripheral nervous systems and exerts its effects by binding to and activating G protein-coupled receptors (i.e., GALR1, GALR2, and GALR3). Galanin Protein, Human (N-His, C-Myc) is the recombinant human-derived Galanin protein, expressed by E. coli , with C-Myc, N-10*His labeled tag. The total length of Galanin Protein, Human (N-His, C-Myc) is 80 a.a., with molecular weight of 16.4 kDa.

HY-P700412

	*GH1/Somatotropin Protein, Human (HEK293, N-His, C-Myc)* GH; GH-N; GHN; hGH-N; Growth hormone; Pituitary growth hormone; growth hormone 1; GH1; IGHD1B; Somatotropin; hGH	Human	HEK293
	Growth hormone (GH) plays a key role in growth control, stimulating the release of insulin-like growth factor 1 (IGF-1) from the liver and tissues to promote body growth. It regulates myoblast differentiation and proliferation and contributes significantly to overall organismal development. GH1/Somatotropin Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GH1/Somatotropin protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of GH1/Somatotropin Protein, Human (HEK293, N-His, C-Myc) is 191 a.a., with molecular weight of 27.2 kDa.

HY-P700487

	*FGF2 Protein, Chicken (N-His, C-Myc)* Fibroblast Growth Factor 2; FGF-2; Basic Fibroblast Growth Factor; bFGF; Heparin-Binding Growth Factor 2; HBGF-2; Fgf2; Fgf-2	Others	E. coli
	FGF2 Protein acts as a ligand for FGFR1-4 and an integrin ligand for FGF2 signaling. It regulates cell survival, division, differentiation, and migration. FGF2 Protein is a strong mitogen and can induce angiogenesis. FGF2 Protein, Chicken (N-His, C-Myc) is the recombinant FGF2 protein, expressed by E. coli, with C-Myc, N-10*His labeled tag. The total length of FGF2 Protein, Chicken (N-His, C-Myc) is 146 a.a., with molecular weight of 23.8 kDa.

HY-P700632

	*IL-17A Protein, Pig (N-His, C-Myc)* Interleukin-17A; IL-17; IL-17A; Cytotoxic T-Lymphocyte-Associated Antigen 8; CTLA-8; IL17A; CTLA8; IL17	Pig	E. coli
	In summary, IL-17A participates in multiple immune responses and plays a critical role in maintaining epithelial barrier integrity, promoting neutrophil recruitment, and enhancing host defense against bacterial, fungal, and viral infections. IL-17A Protein, Pig (N-His, C-Myc) is the recombinant pig-derived IL-17A protein, expressed by E. coli , with C-Myc, N-10*His labeled tag. The total length of IL-17A Protein, Pig (N-His, C-Myc) is 130 a.a., with molecular weight of 22.4 kDa.

HY-P700468

	*GLP1R Protein, Human (HEK293, N-His, C-Myc)* rHuGlucagon-like peptide 1 receptor/GLP1R, Fc; Glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R	Human	HEK293
	The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of GLP1R Protein, Human (HEK293, N-His, C-Myc) is 122 a.a., with molecular weight of 33 kDa.

HY-P700488

	*HDGF Protein, Mouse (P. pastoris, N-His, C-Myc)* rHuHepatoma-derived growth factor/HDGF, His; Hepatoma-Derived Growth Factor; HDGF; High Mobility Group Protein 1-Kike 2; HMG-1L2; HDGF; HMG1L2	Mouse	P. pastoris
	HDGF Protein, a transcriptional repressor, promotes fibroblast mitogenic activity. Existing as a monomer or domain-swapped homodimer, it interacts with nuclear proteins NCL and YBX1/YB1. HDGF Protein, Mouse (P. pastoris, N-His, C-Myc) is the recombinant mouse-derived HDGF protein, expressed by P. pastoris, with C-Myc, N-10*His labeled tag. The total length of HDGF Protein, Mouse (P. pastoris, N-His, C-Myc) is 237 a.a., with molecular weight of 30.3 kDa.

HY-P700467

	*TPBG/5T4 Protein, Cynomolgus (HEK293, N-His, C-Myc)* rCynTrophoblast glycoprotein/5T4, His; TPBG; 5T4 Protein, Human; 5T4AG Protein, Human; M6P1 Protein, Human; WAIF1 Protein, Human	Cynomolgus	HEK293
	TPBG/5T4 protein blocks Wnt3a-dependent LRP6 internalization by indirectly interacting with LRP6, thereby potentially inhibiting Wnt/β-catenin signaling. This unique mechanism suggests that TPBG/5T4 plays a crucial role in regulating the Wnt/β-catenin pathway by disrupting LRP6 internalization and affecting downstream signaling. TPBG/5T4 Protein, Cynomolgus (HEK293, N-His, C-Myc) is the recombinant cynomolgus-derived TPBG/5T4 protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of TPBG/5T4 Protein, Cynomolgus (HEK293, N-His, C-Myc) is 321 a.a., with molecular weight of 39.9 kDa.

HY-P700603

	*GUCY2C/Guanylyl cyclase C Protein, Mouse (HEK293, N-His, C-Myc)* Guanylyl cyclase C; GC-C; STAR; GUCY2C; GUC2C; STA receptor; DIAR6; EC 4.6.1; GCC; GUC2CEC 4.6.1.2; MUCIL	Mouse	HEK293
	GUCY2C, a vital guanylyl cyclase, catalyzes the synthesis of cyclic cGMP from GTP. GUCY2C/Guanylyl cyclase C Protein, Mouse (HEK293, N-His, C-Myc) is the recombinant mouse-derived GUCY2C/Guanylyl cyclase C protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of GUCY2C/Guanylyl cyclase C Protein, Mouse (HEK293, N-His, C-Myc) is 414 a.a., with molecular weight of 52.1 kDa.

HY-P700433

	*CD30/TNFRSF8 Protein, Human (HEK293, N-His, C-Myc)* rHuTumor necrosis factor receptor superfamily member 8/CD30, His; Tumor necrosis factor receptor superfamily member 8; CD30L receptor; Ki-1 antigen; Lymphocyte activation antigen CD30; CD30; TNFRSF8	Human	HEK293
	CD30/TNFRSF8, a receptor for TNFSF8/CD30L, regulates cellular growth and lymphoblast transformation. It activates NF-kappa-B, modulating gene expression. Interactions with TRAF1, TRAF2, TRAF3, and TRAF5 indicate involvement in complex signaling networks. Engagement with TNFSF8 implies impact on immune responses and cellular homeostasis, emphasizing its significance in fundamental biological processes. CD30/TNFRSF8 Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived CD30/TNFRSF8 protein, expressed by HEK293, with C-Myc, N-10*His labeled tag. The total length of CD30/TNFRSF8 Protein, Human (HEK293, N-His, C-Myc) is 361 a.a., with molecular weight of 43.5 kDa.

HY-P701099

	*Intelectin-1/ITLN1 Protein, Human (N-His, C-myc)* ITLN1; intelectin 1 (galactofuranose binding); intelectin-1; FLJ20022; hIntL; HL 1; ITLN; LFR; ITLN-1; endothelial lectin HL-1; galactofuranose-binding lectin; intestinal lactoferrin receptor; HL1; HL-1; INTL; omentin	Human	E. coli
	Intelectin-1/ITLN1 is a lectin with specific affinity for microbial carbohydrate chains and recognizes β-linked D-galactofuranosose, D-glycerolphosphate modified glycans, D-glycerol-D-talo-oct- 2-ulosonic acid (KO) and 3-deoxy-D-manno-oct-2-keto acid (KDO). It binds to bacterial glycans and helps defend against microorganisms. Intelectin-1/ITLN1 Protein, Human (N-His, C-myc) is the recombinant human-derived Intelectin-1/ITLN1 protein, expressed by E. coli , with N-10*His, C-Myc labeled tag. The total length of Intelectin-1/ITLN1 Protein, Human (N-His, C-myc) is 280 a.a., with molecular weight of ~38.6 kDa.

HY-P700541

	*CCR2 Protein, Mouse (N-His, C-Myc)* CCR2; chemokine (C-C motif) receptor 2; CMKBR2; CC CKR 2; CD192; CKR2; FLJ78302; MCP 1 R; CCR2A; CCR2B; CKR2A; CKR2B; MCP-1-R; CC-CKR-2	Mouse	E. coli
	CCR2 protein is an important chemokine receptor that coordinates chemotaxis and migration by binding to CCL2, CCL7, and CCL12 and activating the PI3K cascade. In addition to chemokine signaling, CCR2 regulates T cell inflammatory cytokines, promotes Th17 cell generation, and promotes mature thymocyte output. CCR2 Protein, Mouse (N-His, C-Myc) is the recombinant mouse-derived CCR2 protein, expressed by E. coli , with C-Myc, N-10*His labeled tag. The total length of CCR2 Protein, Mouse (N-His, C-Myc) is 55 a.a., with molecular weight of 13.6 kDa.

HY-P700616

	*ANO1/Anoctamin-1 Protein, Human (N-His, C-Myc)* anoctamin 1, calcium activated chloride channel; oral cancer overexpressed 2, ORAOV2, TMEM16A, transmembrane protein 16A; anoctamin-1; DOG1; FLJ10261; TAOS2; oral cancer overexpressed 2; tumor-amplified and overexpressed sequence 2; discovered on gastrointestinal stromal tumors protein 1; transmembrane protein 16A (eight membrane-spanning domains); ORAOV2; TMEM16A	Human	E. coli
	ANO1/Anoctamin-1 protein, a calcium-activated chloride channel (CaCC), plays diverse roles in cellular functions. It serves as a major contributor to basal and stimulated chloride conductance in airway epithelial cells, impacting tracheal cartilage development and contributing to airway mucus expression induced by interleukins IL3 and IL8, as well as by the asthma-associated protein CLCA1. ANO1 is indispensable for normal functioning of the interstitial cells of Cajal (ICCs), crucial for electrical pacemaker activity in gastrointestinal smooth muscles, and is involved in transepithelial anion transport and smooth muscle contraction. It is also required for CFTR activation and membrane expression, modulating endoplasmic reticulum Ca(2+) store release. Additionally, ANO1 participates in calcium-activated chloride secretion in human sweat gland epithelial cells, showing increased basal chloride permeability and decreased Ca(2+)-induced chloride permeability. In sensory neurons, ANO1 acts as a heat sensor and modulates spontaneous firing patterns, contributing to calcium-activated chloride channel activity in taste cells and mediating non-histaminergic Mas-related G-protein coupled receptor (MRGPR)-dependent itching in dorsal root ganglion neurons. In the developing brain, ANO1 is essential for the Ca(2+)-dependent process extension of radial glial cells. ANO1/Anoctamin-1 Protein, Human (N-His, C-Myc) is the recombinant human-derived ANO1/Anoctamin-1 protein, expressed by E. coli , with C-Myc, N-10*His labeled tag. The total length of ANO1/Anoctamin-1 Protein, Human (N-His, C-Myc) is 87 a.a., with molecular weight of ~17.6 kDa.

HY-P700567

	*PLA2G7 Protein, Mouse (Baculovirus, N-His, C-Myc)* PLA2G7; phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma); platelet-activating factor acetylhydrolase; LDL PLA2; PAFAH; LDL-PLA(2); gVIIA-PLA2; PAF 2-acylhydrolase; PAF acetylhydrolase; group-VIIA phospholipase A2; LDL-associated phospholipase A2; lipoprotein-associated phospholipase A2; 1-alkyl-2-acetylglycerophosphocholine esterase; 2-acetyl-1-alkylglycerophosphocholine esterase; PAFAD; LP-PLA2; LDL-PLA2	Mouse	Sf9 insect cells
	The PLA2G7 protein is a lipoprotein-associated calcium-independent phospholipase A2 that plays a key role in phospholipid catabolism during inflammation and oxidative stress responses. It acts at the lipid-water interface and hydrolyzes the ester bond of the fatty acyl group at the sn-2 position, with particular preference for short-chain fatty acyl groups. PLA2G7 Protein, Mouse (Baculovirus, N-His, C-Myc) is the recombinant mouse-derived PLA2G7 protein, expressed by Sf9 insect cells , with C-Myc, N-10*His labeled tag. The total length of PLA2G7 Protein, Mouse (Baculovirus, N-His, C-Myc) is 419 a.a., with molecular weight of 50.7 kDa.

HY-P700568

	*PLA2G7 Protein, Mouse (HEK293, N-His, C-Myc)* PLA2G7; phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma); platelet-activating factor acetylhydrolase; LDL PLA2; PAFAH; LDL-PLA(2); gVIIA-PLA2; PAF 2-acylhydrolase; PAF acetylhydrolase; group-VIIA phospholipase A2; LDL-associated phospholipase A2; lipoprotein-associated phospholipase A2; 1-alkyl-2-acetylglycerophosphocholine esterase; 2-acetyl-1-alkylglycerophosphocholine esterase; PAFAD; LP-PLA2; LDL-PLA2	Mouse	HEK293
	The PLA2G7 protein is a lipoprotein-associated calcium-independent phospholipase A2 that plays a key role in phospholipid catabolism during inflammation and oxidative stress responses. It acts at the lipid-water interface and hydrolyzes the ester bond of the fatty acyl group at the sn-2 position, with particular preference for short-chain fatty acyl groups. PLA2G7 Protein, Mouse (HEK293, N-His, C-Myc) is the recombinant mouse-derived PLA2G7 protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of PLA2G7 Protein, Mouse (HEK293, N-His, C-Myc) is 419 a.a., with molecular weight of 51.9 kDa.

HY-P72159

	*CXCR4 Protein, Human (N-His-SUMO, C-Myc)* C-X-C chemokine receptor type 4; CD184; CD184 antigen; Chemokine C X C motif; receptor 4; Chemokine CXC Motif Receptor 4; CXC-R4; CXCR-4; CXCR4; CXCR4_HUMAN; D2S201E; FB22; Fusin; HM89; HSY3RR; LAP 3; LAP3; LCR1; LESTR; NPY3R; NPYR; NPYRL; NPYY3; NPYY3R; SDF 1 receptor; SDF-1 receptor; WHIM; WHIMS	Human	E. coli
	The CXCR4 protein functions as a receptor for the CXC chemokine CXCL12/SDF-1, triggering an increase in intracellular calcium ions and activation of MAPK1/MAPK3. It is actively involved in AKT signaling, which is critical for regulating cell migration, especially in wound healing. CXCR4 Protein, Human (N-His-SUMO, C-Myc) is the recombinant human-derived CXCR4 protein, expressed by E. coli , with N-10*His, C-Myc, N-SUMO labeled tag. The total length of CXCR4 Protein, Human (N-His-SUMO, C-Myc) is 50 a.a., with molecular weight of ~28 kDa.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks